查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1495998

全球安全針市場 - 2024年至2029年預測

Global Safety Needles Market - Forecasts from 2024 to 2029
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 117 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

2022年安全針市值為429,215,000美元，預計2029年將達到1,002,348,000美元，複合年成長率為12.88%。

安全針是一種先進的需求，具有內建的安全機制，可以避免針刺傷患者。預計在預測期內推動市場成長的關鍵原因是疾病的增加和增加疫苗接種以避免慢性病。隨著生活方式變得更加複雜，慢性病盛行率增加，診斷、治療和免疫接種的支出大幅增加，安全針市場不斷擴大。

此外，為了更好地預防有害病原體進入體內的潛在感染，對一次性安全針頭的需求也為產業擴張提供了新的機會。此外，老年人口的增加以及對改善身體結構的安全針的需求也推動了市場的成長。政府對醫療保健領域的大力投資預計也將帶來穩定成長。

從地區來看，調查分為北美、南美、歐洲、中東/非洲和亞太地區。亞太地區和北美地區預計將佔據主要市場佔有率。亞太地區正在成為醫療保健中心。與他們的祖國相比，美國人和歐洲人發現該地區的治療具有成本效益且便宜。透過在亞太地區接受治療，普通美國人可以節省高達 90% 的醫療保健費用。而且，該地區醫療基礎設施和設施的增加預計將進一步擴大醫療旅遊市場，並帶來安全針的顯著成長。

在歐洲地區，由於老年人口比例較高以及慢性病，特別是心血管疾病的顯著增加，對用於診斷、治療和藥物攝入的安全注射器的需求預計將增加。

市場促進因素：

  • 醫療保健支出的增加和疾病發生率的上升預計將擴大市場。

推動安全注射器市場成長的關鍵原因之一是醫療保健支出和疾病案例的增加。隨著生活方式變得更加複雜，心血管疾病的病例正在迅速增加。診斷、治療和藥物攝取量顯著增加，增加了安全針的適用性。根據世界衛生組織（WHO）的資料，2019年有17.9名患者死於心血管疾病，佔當年死亡人數的32%。 646萬65歲以下的人死於CVD。

慢性病的增加顯著增加了醫療保健成本，以改善醫療保健。根據世界銀行資料，全球人均衛生支出從2015年的999.104美元增加到2018年的1,111.082美元。醫療成本和治療費用的上漲預計將推動安全針頭市場的激增。

此外，國際組織也正在採取舉措，透過提高意識提升計劃、藥物和治療來減輕慢性病的負擔。世衛組織的目標是在 2010 年至 2025 年間將全球血壓問題的盛行率降低 25%。世衛組織宣布，到 2025 年，該計劃的 50% 受益者將接受持續的藥物治療和其他治療，以預防與 CVD 相關的死亡。預防和治療的良好前景預計將擴大市場機會。

市場限制因素：

  • 注射器和針頭廢棄物的增加會造成環境威脅，進而阻礙市場的發展。

安全針產業面臨的一個主要問題是針處置。安全注射器主要是一次性注射器，其處置不當會造成注射器和針頭的污染。隨著針頭和注射器使用的增加，世界各地的注射器污染急劇增加。 2021 年 3 月，舊金山共收集了超過 13,000 個注射器和廢棄物，比 10 年前增加了 10 倍。此外，針頭處理不當會增加傳播愛滋病毒和肝炎等疾病的可能性。蓬勃發展的注射器市場預計將進一步增加污染，這會導致環境惡化，因此引起人們的擔憂。

主要發展

  • 2023 年 1 月 - MTD 集團的 DropSafeTM SicuraTM 被動安全針頭獲得 FDA 批准，用於肌肉內和皮下注射疫苗和藥物。該針頭旨在消除針刺傷害，並提供完全安全的注射體驗。針頭受到透明護罩的保護，注射後會自動鎖定，無需醫療保健專業人員 (HCP) 逐步啟動。 HCP 安全一直是 MTD Group 的首要任務，DropSafeTM SicuraTM 將在美國各地的藥房連鎖店和其他醫療機構提供。
  • 2023 年 1 月 - Milestone Scientific 與瑞典和 Martina 合作，在西班牙、葡萄牙和法國銷售 STA 單牙麻醉系統(R)。該協議賦予瑞典和瑪蒂娜 STA 在這些市場的獨家經銷權，並取代其目前在義大利的經銷商。 STA 系統採用數位化、電腦控制的精確劑量，可提供無痛注射、縮短等待時間、減少併發症和減少患者取消注射。
  • 2022 年 11 月 - Neogen Corporation 為生產農民推出了一款新型雙感測針，增強了 Ideal® D3™ 感測針的有效性。正在申請專利的 D3X 針是 Neogen Corporation 的金屬合金針，其側壁經過加固，可提高負載強度並降低彎曲或斷裂的風險。此外，還使用了高度可見的紅色提取環，以防止針頭陷入動物的皮膚中。
  • 2022 年 3 月 - NuGen Medical Devices 與 Harrington Consultants Limited 和 Al Mufid Pharmaceuticals 簽署了一份為期五年的無針注射器 InsuJet(TM) 經銷協議。該合約將為科威特支付至少 200 萬加元，但須經科威特衛生局核准。科威特成年人糖尿病盛行率為24.9%，位居世界第三。 InsuJet(TM) 是加拿大衛生署核准的第一個自行注射無針注射系統，為數百萬患有糖尿病和其他慢性病的患者提供安全且經濟高效的藥物輸送。

主要市場區隔

按類型

  • 主動安全針
  • 被動安全針

依給藥途徑

  • 皮下的
  • 靜脈
  • 其他

按最終用戶

  • 醫院/診所
  • 門診治療中心
  • 診斷中心
  • 其他

按地區

  • 北美洲
  • 美國
  • 加拿大
  • 墨西哥
  • 南美洲
  • 巴西
  • 阿根廷
  • 其他
  • 歐洲
  • 英國
  • 德國
  • 義大利
  • 法國
  • 其他
  • 中東/非洲
  • 阿拉伯聯合大公國
  • 沙烏地阿拉伯
  • 其他
  • 亞太地區
  • 日本
  • 中國
  • 印度
  • 韓國
  • 台灣
  • 泰國
  • 印尼
  • 其他

目錄

第1章簡介

  • 市場概況
  • 市場定義
  • 調查範圍
  • 市場區隔
  • 貨幣
  • 先決條件
  • 基準年和預測年時間表
  • 相關利益者的主要利益

第2章調查方法

  • 研究設計
  • 調查過程

第3章執行概述

  • 主要發現

第4章市場動態

  • 市場促進因素
  • 市場限制因素
  • 波特五力分析
  • 產業價值鏈分析
  • 分析師觀點

第5章全球安全針市場：按類型

  • 介紹
  • 主動安全針
  • 被動安全針

第6章全球安全針市場：依給藥途徑分類

  • 介紹
  • 皮下的
  • 靜脈
  • 其他

第7章全球安全針市場：依最終用戶分類

  • 介紹
  • 醫院和診所
  • 門診治療中心
  • 診斷中心
  • 其他

第8章全球安全針市場：按地區

  • 介紹
  • 北美洲
  • 南美洲
  • 歐洲
  • 中東/非洲
  • 亞太地區

第9章競爭環境及分析

  • 主要企業及策略分析
  • 市場佔有率分析
  • 合併、收購、協議和合作
  • 競爭對手儀表板

第10章 公司簡介

  • BD
  • Cardinal Health
  • B. Braun Melsungen Ag
  • Medline Industries, Inc.
  • Johnson & Johnson Services, Inc.
  • Nipro Medical Corporation
  • Smith's Group Plc
  • Metier Medical Limited
  • Olympus Corporation
簡介目錄
Product Code: KSI061611907

The global safety needles market was valued at US$429.215 million in 2022 and is forecasted to reach US$1,002.348 million by 2029, growing at a CAGR of 12.88%.

Safety needles are advanced needs having the feature of an inbuilt safety mechanism that can avoid needle-linked injuries to the patients. The prime reason that is expected to drive the market growth during the forecasted period is the growing advent of diseases and rising vaccination in an attempt to avoid chronic diseases. With rising complexities in lifestyle and the growing prevalence of chronic diseases, expenditure on diagnosis, treatments, and vaccinations has surged significantly, which has increased the market for safe needles.

Furthermore, the demand for single-use safety needles for better prevention against potential infection of unwanted pathogens entering the body has provided a new opportunity for the industry's expansion. Moreover, an increase in the geriatric population and demand for safe needles for better body suitability also drive the market growth. Robust investment by the government in the healthcare sector is also projected to provide stable growth.

Geographically, the global safety needles are divided into North America, South America, Europe, the Middle East and Africa, and the Asia Pacific regions for the study. The Asia Pacific and North American regions are expected to hold a significant market share. The Asia Pacific region has been emerging as a medical hub. Compared to their countries, Americans and the European population find medical treatment in this region more cost-effective and cheaper. An average American can save up to 90% of the expenditure on healthcare if the patient gets treatment from the Asia Pacific region. Furthermore, rising healthcare infrastructure and facilities in the region will further expand the medical tourism market and provide substantial growth for safety needles.

The European region has observed a high rise in the proportion of the geriatric population and a significant increase in chronic, especially cardiovascular disease, which is projected to create the demand for safe syringes for diagnosis, treatment, and medicine intake.

Market Drivers:

  • Rising healthcare expenditure and instances of diseases are expected to increase the market.

One of the prime reasons driving the market growth of safety needles is rising healthcare expenditure and instances of diseases. With growing complexities in lifestyle, a surge in cases of cardiovascular diseases has increased. Diagnosis, treatment, and medicine intake have increased significantly, which has raised safety needle adaption. Data from the World Health Organization (WHO) shows that in 2019, 17.9 patients lost their lives owing to cardiovascular illnesses, which accounted for 32% of deaths in the year. 6.460 million deaths among patients under 65 years of age were caused by CVDs.

Rising instances of chronic diseases have significantly increased health expenditure for better healthcare. Data from the World Bank shows that per capita health expenditure has increased globally from US$999.104 in 2015 to US$1,111.082 in 2018. Increasing health expenditure and treatment are expected to surge the market for safety needles.

Furthermore, international organizations have also taken the initiative to reduce the burden of chronic diseases through awareness programs, medication, and treatments. WHO aims to reduce the global prevalence of blood pressure issues by 25% from 2010 to 2025. WHO declared that 50% of the beneficiaries under this program will receive continuous drug therapy and other treatments to prevent CVD-linked death by 2025. Promising prevention and treatment prospects are expected to increase market opportunities.

Market Restraint:

  • Rising syringe and needle waste create an environmental threat that could hamper the market.

A major problem faced by the safety needle industry is the disposal of needles. Safety syringes are predominantly single-use syringes, and their improper disposal creates syringes and needles pollution. With the rising usage of needles and syringes, a surge in syringe pollution has been observed worldwide. In March 2021, San Francisco collected more than 13,000 syringes and needles waste, an increase of 10 times than a decade ago. Furthermore, improper disposal of needles raises the chances of spreading diseases such as HIV and hepatitis. The surging needles market is expected to increase further pollution, which degrades the environment and hence has raised concerns.

Key Developments:

  • January 2023- MTD Group received FDA clearance for its DropSafeTM SicuraTM passive safety needle for intramuscular and subcutaneous injection of vaccines and drugs. The needle is designed to eliminate needlestick injuries, providing a fully safe injection experience. The needle is protected by a transparent shield that automatically locks after injection, requiring no incremental activation step by the healthcare professional (HCP). The safety of HCPs always been a top priority for MTD Group, and the DropSafeTM SicuraTM is going to be available to pharmacy chains and other healthcare practices in the US.
  • January 2023- Milestone Scientific partnered with Sweden & Martina to distribute its STA Single Tooth Anesthesia System(R) in Spain, Portugal, and France. The agreement grants Sweden & Martina exclusive rights to market STA in these markets, replacing its current distributor in Italy. The STA system, which uses precise, digitized, and computer-controlled dosing, offers painless injections, shorter wait times, fewer complications, and reduced patient cancellations. The partnership aims to grow dentists' business and improve patient experience.
  • November 2022- Neogen Corporation introduced a new dual-detecting needle for production farmers, enhancing the effectiveness of its Ideal(R) D3(TM) detectable needles. The patent-pending D3X needles feature Neogen's metal alloy needles with stronger side walls, increasing load strength and reducing the risk of bending and breaking. They also feature a highly visible red extraction collar to prevent needles from submerging in animal skin. The new needles offer increased visibility, quick removal, and increased efficiency, ensuring food safety and preventing needles from reaching consumers.
  • March 2022- NuGen Medical Devices signed a 5-year distribution agreement with Harrington Consultants Limited and Al Mufid Pharmaceuticals for the distribution of its needle-free injection device, InsuJet(TM). The agreement cover Kuwait for at least CA$ 2,000,000, with regulatory approval from Kuwait Health Authorities. Kuwait ranks third globally for adult diabetes prevalence at 24.9%. InsuJet(TM) is the first self-administered needle-free injection system approved by Health Canada, providing safe and cost-effective drug delivery for millions of patients suffering from diabetes or other chronic illnesses.

Key Market Segments:

By Type

  • Active Safety Needles
  • Passive Safety Needles

By Route Of Administration

  • Subcutaneous
  • Intravenous
  • Others

By End Users

  • Hospitals and clinics
  • Ambulatory care centers
  • Diagnostic centers
  • Others

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • Italy
  • France
  • Others
  • Middle East and Africa
  • UAE
  • Saudi Arabia
  • Others
  • Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Taiwan
  • Thailand
  • Indonesia
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base and Forecast Years Timeline
  • 1.8. Key Benefits to the Stakeholder

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Processes

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.5. Analyst View

5. GLOBAL SAFETY NEEDLES MARKET BY TYPE

  • 5.1. Introduction
  • 5.2. Active Safety Needles
    • 5.2.1. Market Opportunities and Trends
    • 5.2.2. Growth Prospects
    • 5.2.3. Geographic Lucrativeness
  • 5.3. Passive Safety Needles
    • 5.3.1. Market Opportunities and Trends
    • 5.3.2. Growth Prospects
    • 5.3.3. Geographic Lucrativeness

6. GLOBAL SAFETY NEEDLES MARKET BY ROUTE OF ADMINISTRATION

  • 6.1. Introduction
  • 6.2. Subcutaneous
    • 6.2.1. Market Opportunities and Trends
    • 6.2.2. Growth Prospects
    • 6.2.3. Geographic Lucrativeness
  • 6.3. Intravenous
    • 6.3.1. Market Opportunities and Trends
    • 6.3.2. Growth Prospects
    • 6.3.3. Geographic Lucrativeness
  • 6.4. Others
    • 6.4.1. Market Opportunities and Trends
    • 6.4.2. Growth Prospects
    • 6.4.3. Geographic Lucrativeness

7. GLOBAL SAFETY NEEDLES MARKET BY END USERS

  • 7.1. Introduction
  • 7.2. Hospitals and Clinics
    • 7.2.1. Market Opportunities and Trends
    • 7.2.2. Growth Prospects
    • 7.2.3. Geographic Lucrativeness
  • 7.3. Ambulatory Care Centers
    • 7.3.1. Market Opportunities and Trends
    • 7.3.2. Growth Prospects
    • 7.3.3. Geographic Lucrativeness
  • 7.4. Diagnostic centers
    • 7.4.1. Market Opportunities and Trends
    • 7.4.2. Growth Prospects
    • 7.4.3. Geographic Lucrativeness
  • 7.5. Others
    • 7.5.1. Market Opportunities and Trends
    • 7.5.2. Growth Prospects
    • 7.5.3. Geographic Lucrativeness

8. GLOBAL SAFETY NEEDLES MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. By Type
    • 8.2.2. By Route of Administration
    • 8.2.3. By End Users
    • 8.2.4. By Country
      • 8.2.4.1. USA
        • 8.2.4.1.1. Market Opportunities and Trends
        • 8.2.4.1.2. Growth Prospects
      • 8.2.4.2. Canada
        • 8.2.4.2.1. Market Opportunities and Trends
        • 8.2.4.2.2. Growth Prospects
      • 8.2.4.3. Mexico
        • 8.2.4.3.1. Market Opportunities and Trends
        • 8.2.4.3.2. Growth Prospects
  • 8.3. South America
    • 8.3.1. By Type
    • 8.3.2. By Route of Administration
    • 8.3.3. By End Users
    • 8.3.4. By Country
      • 8.3.4.1. Brazil
        • 8.3.4.1.1. Market Opportunities and Trends
        • 8.3.4.1.2. Growth Prospects
      • 8.3.4.2. Argentina
        • 8.3.4.2.1. Market Opportunities and Trends
        • 8.3.4.2.2. Growth Prospects
      • 8.3.4.3. Others
        • 8.3.4.3.1. Market Opportunities and Trends
        • 8.3.4.3.2. Growth Prospects
  • 8.4. Europe
    • 8.4.1. By Type
    • 8.4.2. By Route of Administration
    • 8.4.3. By End Users
    • 8.4.4. By Country
      • 8.4.4.1. United Kingdom
        • 8.4.4.1.1. Market Opportunities and Trends
        • 8.4.4.1.2. Growth Prospects
      • 8.4.4.2. Germany
        • 8.4.4.2.1. Market Opportunities and Trends
        • 8.4.4.2.2. Growth Prospects
      • 8.4.4.3. Italy
        • 8.4.4.3.1. Market Opportunities and Trends
        • 8.4.4.3.2. Growth Prospects
      • 8.4.4.4. France
        • 8.4.4.4.1. Market Opportunities and Trends
        • 8.4.4.4.2. Growth Prospects
      • 8.4.4.5. Others
        • 8.4.4.5.1. Market Opportunities and Trends
        • 8.4.4.5.2. Growth Prospects
  • 8.5. Middle East and Africa
    • 8.5.1. By Type
    • 8.5.2. By Route of Administration
    • 8.5.3. By End Users
    • 8.5.4. By Country
      • 8.5.4.1. UAE
        • 8.5.4.1.1. Market Opportunities and Trends
        • 8.5.4.1.2. Growth Prospects
      • 8.5.4.2. Saudi Arabia
        • 8.5.4.2.1. Market Opportunities and Trends
        • 8.5.4.2.2. Growth Prospects
      • 8.5.4.3. Others
        • 8.5.4.3.1. Market Opportunities and Trends
        • 8.5.4.3.2. Growth Prospects
  • 8.6. Asia Pacific
    • 8.6.1. By Type
    • 8.6.2. By Route of Administration
    • 8.6.3. By End Users
    • 8.6.4. By Country
      • 8.6.4.1. Japan
        • 8.6.4.1.1. Market Opportunities and Trends
        • 8.6.4.1.2. Growth Prospects
      • 8.6.4.2. China
        • 8.6.4.2.1. Market Opportunities and Trends
        • 8.6.4.2.2. Growth Prospects
      • 8.6.4.3. India
        • 8.6.4.3.1. Market Opportunities and Trends
        • 8.6.4.3.2. Growth Prospects
      • 8.6.4.4. South Korea
        • 8.6.4.4.1. Market Opportunities and Trends
        • 8.6.4.4.2. Growth Prospects
      • 8.6.4.5. Taiwan
        • 8.6.4.5.1. Market Opportunities and Trends
        • 8.6.4.5.2. Growth Prospects
      • 8.6.4.6. Thailand
        • 8.6.4.6.1. Market Opportunities and Trends
        • 8.6.4.6.2. Growth Prospects
      • 8.6.4.7. Indonesia
        • 8.6.4.7.1. Market Opportunities and Trends
        • 8.6.4.7.2. Growth Prospects
      • 8.6.4.8. Others
        • 8.6.4.8.1. Market Opportunities and Trends
        • 8.6.4.8.2. Growth Prospects

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. BD
  • 10.2. Cardinal Health
  • 10.3. B. Braun Melsungen Ag
  • 10.4. Medline Industries, Inc.
  • 10.5. Johnson & Johnson Services, Inc.
  • 10.6. Nipro Medical Corporation
  • 10.7. Smith's Group Plc
  • 10.8. Metier Medical Limited
  • 10.9. Olympus Corporation